Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05607186
NCT05607186
Completed
Not Applicable

Outcomes of Neoadjuvant Therapy for Rectal Cancer in a Tertiary Asian

Singapore General Hospital0 sites59 target enrollmentJanuary 1, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRectal CancerOncology

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rectal Cancer
Sponsor
Singapore General Hospital
Enrollment
59
Primary Endpoint
Correlation between mrTRG and pTRG
Status
Completed
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

This is a retrospective cohort study that aims to evaluate the correlation of magnetic resonance tumour regression grade (mrTRG) and pathological TRG (pTRG) of locally advanced rectal cancer after neoadjuvant long course chemoradiotherapy as well as the prognostic value of mrTRG on survival.

Registry
clinicaltrials.gov
Start Date
January 1, 2011
End Date
December 31, 2019
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Rectal cancer
  • •At least 1 high risk feature on MRI
  • •Undergo long course neoadjuvant chemoradiotherapy (LCCRT)

Exclusion Criteria

  • •metastatic disease
  • •Patients who undergo short course radiotherapy
  • •Patients without a repeat MRI after completion of LCCRT

Outcomes

Primary Outcomes

Correlation between mrTRG and pTRG

Time Frame: Between 1 Jan 2011 to 31 Dec 2016

Secondary Outcomes

  • Prognostic value of mrTRG on survival outcomes of rectal cancer patients(Between 1 Jan 2011 to 31 Dec 2016)

Similar Trials

Active, not recruiting
Not Applicable
Predicting Neoadjuvant Therapy Response of Rectal Cancer With MRIRectal Neoplasms
NCT02640586Sun Ying-Shi1,614
Recruiting
Not Applicable
Total Neoadjuvant Treatment of Rectal Cancer by MRI-guided RadiotherapyRectal Cancer
NCT05916040Universitair Ziekenhuis Brussel35
Active, not recruiting
Phase 2
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)Rectal Cancer
NCT04017455The Netherlands Cancer Institute38
Completed
Phase 2
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)Colon CancerRectal Cancer
NCT01363843William Sikov MD39
Completed
Not Applicable
Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for FailureRectal Cancer
NCT04679597Institute of Oncology Ljubljana161